Denfivontinib activates effector T-cells through NLRP3-inflammasome, yielding potent anticancer effects by combination with pembrolizumab.
Kim DK, Synn CB, Lee W, Jo HN, Lee CY, Lee S, Hwang JY, Kim Y, Kang SS, Baek S, Na K, Yang SM, Kim MH, Han H, Han YJ, Kim JH, Park SY, Park YJ, Lee GT, Choi SJ, Sohn JO, Ye SK, Lee JB, Lim SM, Hong MH, Pyo KH, Cho BC.
Kim DK, et al. Among authors: lee cy.
Mol Cancer Ther. 2024 Dec 5. doi: 10.1158/1535-7163.MCT-24-0501. Online ahead of print.
Mol Cancer Ther. 2024.
PMID: 39632711